Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bayer AG (BAYN)
Price€49.82Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €45.58B | €46.61B | €47.64B | €50.74B | €44.08B | €41.40B | €43.55B | €39.59B | €35.02B | €46.77B | €46.32B | €42.24B | €40.16B | €39.76B | €36.53B | €35.09B |
| Gross profit | €26.78B | €25.34B | €27.89B | €30.87B | €27.27B | €22.26B | €26.08B | €22.58B | €23.63B | €26.47B | €25.17B | €21.97B | €21.09B | €21.79B | €19.43B | €19.95B |
| Gross margin | 58.76% | 54.36% | 58.54% | 60.84% | 61.85% | 53.77% | 59.89% | 57.03% | 67.49% | 56.61% | 54.33% | 52.02% | 52.51% | 54.79% | 53.18% | 56.87% |
| Research & development | €5.77B | €6.21B | €5.37B | €6.57B | €5.41B | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | €27.86B | €25.41B | €27.28B | €23.86B | €23.91B | €29.98B | €20.21B | €18.66B | €12.88B | €19.21B | €18.84B | €16.47B | €16.15B | €17.82B | €15.28B | €17.73B |
| Operating income | −€1.08B | −€71.0M | €612.0M | €7.01B | €3.35B | −€7.72B | €5.87B | €3.91B | €10.75B | €7.26B | €6.33B | €5.51B | €4.93B | €3.96B | €4.15B | €2.22B |
| Operating margin | −2.36% | −0.15% | 1.28% | 13.82% | 7.61% | −18.64% | 13.48% | 9.89% | 30.70% | 15.53% | 13.66% | 13.04% | 12.29% | 9.96% | 11.36% | 6.33% |
| EBITDA | €1.92B | €8.81B | €10.45B | €13.03B | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | 4.22% | 18.90% | 21.93% | 25.68% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −€3.60B | −€2.55B | −€2.94B | €4.17B | €1.02B | −€10.49B | €4.11B | €1.71B | €8.09B | €4.83B | €4.10B | €3.44B | €3.19B | €2.50B | €2.47B | €1.31B |
| Net profit margin | −7.89% | −5.46% | −6.18% | 8.21% | 2.32% | −25.33% | 9.44% | 4.32% | 23.12% | 10.32% | 8.85% | 8.15% | 7.93% | 6.28% | 6.77% | 3.73% |
| Basic EPSper basic share | -€3.68 | -€2.60 | -€2.99 | €4.22 | €1.02 | -€10.68 | €4.16 | €1.82 | €8.87 | €5.48 | €4.97 | €4.14 | €3.86 | €2.96 | €2.99 | €1.57 |
| Diluted EPSper diluted share | -€3.68 | -€2.60 | -€2.99 | €4.22 | €1.02 | -€10.68 | €4.16 | €1.82 | €8.87 | €5.48 | €4.97 | €4.14 | €3.86 | €2.96 | €2.99 | €1.57 |
Owners
Reported major voting-rights holders
2.90%of voting rights
Amundi S.A.Notified Sep 23, 2026
View holders
| Holder | Voting rights |
|---|---|
Amundi S.A. | 2.90%Sep 23, 2026 · 28.54M votes |
The Goldman Sachs Group, Inc. | 0.16%Jun 15, 2026 · 1.61M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Issuer voting-rights announcements via EQS ↗Updated Oct 21, 2026
Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
